3,415 results match your criteria American Journal Of Therapeutics[Journal]


Severe Hyponatremia During First Cycle of Cyclophosphamide/Doxorubicin Chemotherapy.

Am J Ther 2022 May 18. Epub 2022 May 18.

Cleveland Clinic.

Syndrome of inappropriate anti-diuretic hormone release (SIDAH) is a condition characterized by an unregulated release of anti-diuretic hormone (ADH) resulting in increased water retention and decreased plasma osmolarity. Without regulation, ADH release will cause a significant decrease in plasma sodium concentration and can present with cramping, nausea, vomiting, and in severe cases, seizures, and potentially falling into a comatose state. The causes of SIADH are variable and range from infections, some malignancies to some medications. Read More

View Article and Full-Text PDF

Clinical Features of Camrelizumab-Associated Diabetes Mellitus.

Am J Ther 2022 May 12. Epub 2022 May 12.

Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, China.

View Article and Full-Text PDF

Naltrexone May Attenuate the Effect of Acamprosate in Patients With Alcohol Use Disorder and Major Depressive Disorder.

Am J Ther 2022 May 10. Epub 2022 May 10.

Department of Psychiatry, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan, ROC.

View Article and Full-Text PDF

Aortic Mural Thrombosis Diagnosed After a Second Dose of mRNA-1273 SARS-CoV-2 Vaccine.

Am J Ther 2022 May-Jun 01;29(3):e358-e361. Epub 2022 Apr 4.

Department of Medicine, Mount Auburn Hospital, Beth Israel-Lahey Health, Cambridge, MA.

View Article and Full-Text PDF

Sertraline-Associated Immunoglobulin A Vasculitis.

Am J Ther 2022 Apr 28. Epub 2022 Apr 28.

Rheumatology, University of Toledo Medical Center, Toledo, OH.

View Article and Full-Text PDF

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

Am J Ther 2022 Apr 28. Epub 2022 Apr 28.

Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China.

View Article and Full-Text PDF

Pharmacological Management of Primary Arterial Hypertension: A Century of Expert Opinions in Cecil Textbook of Medicine.

Am J Ther 2022 May-Jun 01;29(3):e287-e297

Department of Cardiology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Background: Advances in drug therapy for primary (or essential) arterial hypertension have contributed to a significant decrease in the frequency and severity of strokes, coronary artery disease and heart failure, and chronic renal insufficiency.

Study Question: What are the milestones of the changes in the expert approach to the pharmacological management of arterial hypertension in the past century?

Study Design: To determine the changes in the experts' approach to the management of arterial hypertension, as presented in a widely used textbook in the United States.

Data Sources: The chapters presenting the management of arterial hypertension in the 26 editions of Cecil Textbook of Medicine published from 1927 through 2020. Read More

View Article and Full-Text PDF

Use of Anticoagulants in COVID-19: A Review.

Am J Ther 2022 Apr 26. Epub 2022 Apr 26.

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.

Background: Coronavirus disease 2019 (COVID-19) is associated with elevated rates of major and fatal thrombotic events, postulated to be the result of a hypercoagulable state mediated through inflammatory and immunomodulatory mechanisms. Early observational studies showed that disease severity and elevated serum D-dimer levels can predict thrombotic risk in patients hospitalized with COVID-19 and reported an alarming phenomenon of breakthrough thrombosis despite standard-of-care prophylaxis, suggesting the need for enhanced thromboprophylactic strategies.

Areas Of Uncertainty: Data on anticoagulant agent selection, dosing, and duration for COVID-19 inpatients are now poised to inform updated professional society guidance. Read More

View Article and Full-Text PDF

Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis.

Am J Ther 2022 Apr 21. Epub 2022 Apr 21.

Division of Hematology and Oncology, Department of Internal Medicine, University of Toledo, Toledo, OH.

View Article and Full-Text PDF

Digging Into Past HBOC Clinical Trials.

Authors:
George P Biro

Am J Ther 2022 May-Jun 01;29(3):e338-e341. Epub 2022 Apr 20.

Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

View Article and Full-Text PDF

Low-Dose Intravenous Amiodarone-Induced Acute Hepatic Failure.

Am J Ther 2022 May-Jun 01;29(3):e364-e367. Epub 2022 Apr 21.

Department of Emergency Medicine, Wellspan Health, York Hospital, York, PA.

View Article and Full-Text PDF

Boswellia Resin (Frankincense)-Associated Mania.

Am J Ther 2022 Apr 13. Epub 2022 Apr 13.

Duty Medical Officer, Starcare Hospital, Calicut, Kerala, India.

View Article and Full-Text PDF

Rituximab Rescue in Treatment Refractory Hypersensitivity Pneumonitis.

Am J Ther 2022 Apr 14. Epub 2022 Apr 14.

Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH.

View Article and Full-Text PDF

Blood Component Requirements and Erythrocyte Transfusion and Mortality Related to Hemoglobin Deficit in Phase III Trial of Hemoglobin-Based Oxygen Carrier: HBOC-201.

Am J Ther 2022 May-Jun 01;29(3):e279-e286. Epub 2022 Apr 14.

Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Background: Hemoglobin-based oxygen carriers (HBOCs) may cause coagulopathy, changes in total hemoglobin (THb), and affect mortality. Low total hemoglobin concentrations [THb] during hemorrhage may worsen outcomes.

Study Question: The database of the Hemopure HEM-0115 phase III trial was queried to determine the use of platelets, plasma, or cryoprecipitate and compare transfusion requirements and coagulation studies between patients randomized to erythrocyte transfusion or HBOC-201 infusion. Read More

View Article and Full-Text PDF

Drug Therapy for Unexplained Dyspnea in Post-COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil.

Authors:
Peter Manu

Am J Ther 2022 Apr 12. Epub 2022 Apr 12.

Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; and.

View Article and Full-Text PDF

Leflunomide-Associated Pancytopenia.

Am J Ther 2022 Apr 11. Epub 2022 Apr 11.

Division of Rheumatology, Department of Internal Medicine, University of Toledo, Toledo, OH.

View Article and Full-Text PDF

Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19.

Am J Ther 2022 02 10;29(2):e237-e244. Epub 2022 Feb 10.

Department of Emergency Medicine, Orlando Regional Medical Center, Orlando Health, Orlando, FL.

View Article and Full-Text PDF
February 2022

Re: "Commentary" by Rothrock et al. "Meta-Analyses Did Not Establish Improved Mortality With Ivermectin Use in COVID-19".

Am J Ther 2021 12 29;29(2):e233-e237. Epub 2021 Dec 29.

EbMCsquared, a Community Interest Company, Northgate House, Upper Borough Walls, Bath, United Kingdom.

View Article and Full-Text PDF
December 2021

Repurposing Drugs for Post-COVID-19 Fatigue Syndrome: Methylphenidate, Duloxetine, and Brexpiprazole.

Authors:
Peter Manu

Am J Ther 2022 01 3;29(2):e229-e230. Epub 2022 Jan 3.

Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY and Medical Services, South Oaks Hospital, Amityville, NY.

View Article and Full-Text PDF
January 2022

Apixaban: An Optimal Agent for the Treatment of Cancer-Associated Venous Thromboembolism?

Am J Ther 2021 Sep 21;29(2):e212-e218. Epub 2021 Sep 21.

Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak republic; and.

Background: Apixaban, a direct inhibitor of activated coagulation factor X (FXaI), is being frequently selected for treatment and prevention of venous thromboembolism (VTE). Several reports about possible use of oral FXaI in patients with cancer-associated VTE (CA-VTE) have been published recently.

Areas Of Uncertainty: The efficacy/safety profile of oral FXaI anticoagulation in patients with CA-VTE seems promising; however, several problems remain unanswered. Read More

View Article and Full-Text PDF
September 2021

Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.

Am J Ther 2021 Nov 24;29(2):e199-e204. Epub 2021 Nov 24.

Department of Medicine, Center for Integrated Research and Unit of Drug Sciences, University Campus Bio-Medico, Rome, Italy.

Background: Recent trials demonstrated the clinical efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure (HF), regardless of the presence or absence of type 2 diabetes. These data may allow the use of this innovative drug class in clinical routine for treating these patients.

Study Question: We aimed at further clarifying the role of SGLT2i in patients with diagnosis of HF, capitalizing on pooled sample size and heightened power for clinically relevant safety and efficacy outcomes. Read More

View Article and Full-Text PDF
November 2021

Fluvoxamine for Acute COVID-19 Infection: Weak Hypothesis, Predictable Failure.

Authors:
Peter Manu

Am J Ther 2022 May-Jun 01;29(3):e342-e343. Epub 2022 Mar 29.

Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.

View Article and Full-Text PDF

Lutetium-Associated Myopathy: A Case Report.

Am J Ther 2022 Mar 24. Epub 2022 Mar 24.

Medical Oncology Department, Bakırkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

View Article and Full-Text PDF

A Scoping Review of Pharmacological Management of Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2021.

Am J Ther 2022 May-Jun 01;29(3):e305-e321. Epub 2022 Apr 1.

Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Rockford, IL.

Background: Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC), or long-COVID, are signs and symptoms that persist after the acute phase of Coronavirus disease 2019 infection has passed. PASC is newly recognized, and research is ongoing to answer questions about pathology, symptoms, diagnosis, and optimal treatment.

Areas Of Uncertainty: Use of pharmacologic treatment for symptoms of PASC is currently evolving. Read More

View Article and Full-Text PDF

Pneumonitis and Myopericarditis After Booster COVID-19 mRNA Vaccination.

Am J Ther 2022 Mar 25. Epub 2022 Mar 25.

Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY.

View Article and Full-Text PDF